Zimmer Biomet Holdings, Inc. Investigated by the Portnoy Law Firm

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Zimmer Biomet Holdings, Inc., and may file a class action on behalf of investors [1][2]. Group 1: Stock Performance and Financial Results - Zimmer's stock price fell by $15.63, or 15.2%, closing at $87.55 per share on November 5, 2025, following the release of its third quarter 2025 financial results [2]. - The company reported net sales of approximately $2 billion for the third quarter of 2025, attributing the results to weaknesses in Latin America, Emerging Markets in Europe, and non-core businesses [2]. - Zimmer lowered the top end of its full-year organic revenue growth forecast from 4.5% to 4.0%, citing a modest slowdown in the U.S. revision market for hips and knees and continued weakness in restorative therapies [2]. Group 2: Legal Actions and Investor Support - The Portnoy Law Firm is representing investors in pursuing claims related to corporate wrongdoing, with a history of recovering over $5.5 billion for aggrieved investors [2]. - Investors are encouraged to contact the firm for a complimentary case evaluation and to discuss options for recovering losses [1].